This HTML5 document contains 62 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
n22http://linked.opendata.cz/resource/drugbank/drug/DB01329/identifier/pubchem-compound/
dctermshttp://purl.org/dc/terms/
n8http://linked.opendata.cz/resource/mesh/concept/
n23http://linked.opendata.cz/resource/drugbank/drug/DB01329/identifier/pubchem-substance/
n4http://linked.opendata.cz/resource/drugbank/company/
n17http://linked.opendata.cz/resource/drugbank/drug/DB01329/identifier/drugbank/
n15http://linked.opendata.cz/resource/drugbank/drug/DB01329/identifier/national-drug-code-directory/
n13http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n20http://linked.opendata.cz/resource/drugbank/drug/DB01329/identifier/chemspider/
n19http://linked.opendata.cz/resource/drugbank/drug/DB01329/identifier/chebi/
n12http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n7http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n5http://linked.opendata.cz/resource/drugbank/property/
n21http://linked.opendata.cz/resource/drugbank/drug/DB01329/identifier/wikipedia/
xsdhhttp://www.w3.org/2001/XMLSchema#
n16http://linked.opendata.cz/resource/drugbank/drug/DB01329/identifier/pharmgkb/
n18http://linked.opendata.cz/resource/drugbank/drug/DB01329/identifier/kegg-compound/
n10http://linked.opendata.cz/resource/atc/
n9http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01329
rdf:type
n3:Drug
n3:description
Semisynthetic broad-spectrum cephalosporin with a tetrazolyl moiety that is resistant to beta-lactamase. It has been proposed especially against <i>Pseudomonas</i> infections.
n3:generalReferences
# Jones RN, Barry AL: Cefoperazone: a review of its antimicrobial spectrum, beta-lactamase stability, enzyme inhibition, and other in vitro characteristics. Rev Infect Dis. 1983 Mar-Apr;5 Suppl 1:S108-26. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/6221381
n3:group
approved
n3:halfLife
The mean serum half-life is approximately 2.0 hours, independent of the route of administration.
n3:indication
For the treatment of bacterial infections caused by susceptible microorganisms.
owl:sameAs
n12:DB01329 n13:DB01329
dcterms:title
Cefoperazone
adms:identifier
n15:0049-1201-83 n16:PA448849 n17:DB01329 n18:C06883 n19:3493 n20:40204 n21:Cefoperazone n22:44185 n23:46504543
n3:mechanismOfAction
Like all beta-lactam antibiotics, cefoperazone binds to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, causing the inhibition of the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins.
n3:packager
n4:271B3EF8-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
Cefoperazone is excreted mainly in the bile.
n3:synonym
(6R,7R)-7-[[2-[(4-Ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Cefoperazone Cefoperazonum (6R,7R)-7-((R)-2-(4-Ethyl-2,3-dioxo-1-piperazinylcarboxamido)-2-(4-hydroxyphenyl)acetamido)-3-((1-methyl-1H-tetrazol-5-yl)thiomethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-carbonsaeure Cefoperazono
n3:toxicity
Symptoms of overdose include blood in the urine, diarrhea, nausea, upper abdominal pain, and vomiting.
n3:proteinBinding
The degree of reversible protein binding varies with the serum concentration from 93% at 25 mcg/mL to 90% at 250 mcg/mL and 82% at 500 mcg/mL. Cefotetan is 88% plasma protein bound.
n3:synthesisReference
Walter Cabri, "Process for the preparation of highly crystalline sodium cefoperazone." U.S. Patent US20040030127, issued February 12, 2004.
n7:hasConcept
n8:M0003720
n3:IUPAC-Name
n5:271B3EFD-363D-11E5-9242-09173F13E4C5
n3:InChI
n5:271B3F03-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n5:271B3F02-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n5:271B3EFF-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n5:271B3F00-363D-11E5-9242-09173F13E4C5
n3:SMILES
n5:271B3F01-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n5:271B3EFB-363D-11E5-9242-09173F13E4C5
n3:logP
n5:271B3EFC-363D-11E5-9242-09173F13E4C5 n5:271B3EF9-363D-11E5-9242-09173F13E4C5 n5:271B3F14-363D-11E5-9242-09173F13E4C5
n3:logS
n5:271B3EFA-363D-11E5-9242-09173F13E4C5
n9:hasATCCode
n10:J01DD12
n3:H-Bond-Acceptor-Count
n5:271B3F09-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n5:271B3F0A-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n5:271B3F04-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n5:271B3F05-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n5:271B3F07-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n5:271B3F06-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n5:271B3F08-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Enteric bacteria and other eubacteria
n3:casRegistryNumber
62893-19-0
n3:category
n3:Bioavailability
n5:271B3F0F-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n5:271B3F11-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n5:271B3F12-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n5:271B3F13-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n5:271B3F0E-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n5:271B3F0D-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n5:271B3F10-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n5:271B3EFE-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n5:271B3F0B-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n5:271B3F0C-363D-11E5-9242-09173F13E4C5